ArticleScientific reports2025
Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Comorbidities are a significant factor affecting the prognosis of patients with rifampicin-resistant tuberculosis (RR-TB). We evaluated the prevalence of comorbidities and their prognostic effects in a Chinese RR-TB cohort. In this study, we reviewed the clinical data of RR-TB patients who started anti-tuberculosis treatment in China between May 2018 and April 2020 by conducting a multicenter cohort study. A log-binomial regression model was used to analyze the relationship between comorbidities and the treatment outcomes of RR-TB. The burden of comorbidities among RR-TB patients in China was heavy, with 49.45% (670/1355) experiencing at least one comorbidity. The most common comorbidities were diabetes (17.79%), followed by other respiratory diseases (11.14%), other liver and kidney diseases (5.31%), hypertension (5.24%), immunodeficiency (4.94%), viral hepatitis or carriers (3.91%), severe heart disease (2.58%), tumours (1.11%), and chronic kidney disease or renal insufficiency (0.74%). Diabetes (RR = 1.31), severe heart disease (RR = 1.70), tumours (RR = 1.89), hypertension (RR = 1.28), aged ≥ 60 years (RR = 1.64) and 45-59 years (RR = 1.38), ethnic minorities (RR = 1.58), retreatment cases (RR = 1.34), and those not using the bedaquiline regimen (RR = 1.92) significantly increased the risk of unfavorable treatment outcomes. While higher education or above (RR = 0.49), employment (RR = 0.51), and having a normal (R = 0.53) or overweight (R = 0.56) BMI could reduce the risk of unfavorable treatment outcomes. Patients with RR-TB beared a substantial comorbidity burden in China. Notably, the presence of comorbidities such as diabetes, severe cardiac disorders, tumours, and hypertension markedly elevate the risk of adverse treatment outcomes in these patients. It is necessary to strengthen the screening and management of comorbidities to optimize the treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.